Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology

Overgaard, Jens; González, Dionisio González; Hulshof, M.C.C.M.; Arcangeli, Giorgio; Dahl, Olav; Mella, Olav; Bentzen, Søren M.

doi:10.3109/02656739609023685

Cited by 234 publications

(55 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Assuming that the skin uptakes in the two studies are comparable, the results would appear to suggest a selective uptake of and conversion of ALA by the DS-sarcoma used in the present study, which may reflect tumour-specific differences in the haem metabolic pathways and/or differences in ALA uptake. studies have demonstrated a clear benefit when HT is combined with other therapy modalities, in particular radiotherapy (Overgaard et al, 1996;Vernon et al, 1996;Prosnitz et al, 1999;van der Zee et al, 2000). A number of experimental studies, both in vitro and in vivo have also suggested a possible role for HT in combination with PDT, a therapy form that is currently being applied to a number of malignant and nonmalignant conditions .…”

Section: Resultsmentioning

confidence: 99%

Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours

et al. 2003

View full text Add to dashboard Cite

The possibility of enhancing aminolaevulinic acid (ALA)-based photodynamic therapy (PDT) by simultaneous application of localised hyperthermia (HT) was evaluated. Treatments of rat DS-sarcomas included: (i) control, (ii) ALA administration (375 mg kg À1 , i.p.), no illumination, (iii) 'nonthermal' illumination, (iv) ALA-PDT: that is, ALA administration, 'nonthermal' illumination, (v) localised HT, 431C, 60 min (vi) ALA-PDT þ HT: ALA administration with full spectrum irradiation resulting in ALA-PDT and HT. Tumour volume was monitored for 90 days or until a target volume (3.5 ml) was reached. No differences were seen between the first three groups, with all tumours reaching the target volume by 8 -11 days. A total of 13 and 15% of tumours did not reach the target volume by day 90 following HT or ALA-PDT treatment, respectively. ALA-PDT þ HT showed the greatest antitumour effect (P ¼ 0.0001), with 61% of the tumours not reaching the target volume. Viability and in vitro growth were also assessed in cells from tumours excised after treatment. ALA-PDT þ HT reduced the fraction of viable tumour cells by 85%, and in vitro culture showed pronounced growth delay compared to control cells. These results demonstrate an enhanced antitumour effect upon ALA þ HT, which appears to involve direct cell toxicity rather than solely vascular damage.

show abstract

Section: Resultsmentioning

confidence: 99%

Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours

et al. 2003

View full text Add to dashboard Cite

show abstract

“…The goal of the method is to deposit heat energy in tumours. The clinical effect of hyperthermia is closely related to thermal parameters (the minimal or maximal temperature) achieved in the malignant tumour (12). However, descriptions of thermal dose including both temperature and time are superior to more simple recordings (14).…”

Section: Thermometry and Quality Assurancementioning

confidence: 99%

“…Using a similar transgluteal technique for most patients, the Berlin Group reported that 19% of catheters had to be removed because of side effects such as local inflammation, pain or abscess formation when used for deep-seated tumours (19). In 300 patients with 1 491 deep-heating sessions from the Duke University in the USA, the complication incidence was 11%, of which 4% of patients were scored as serious (12). This group reported only 2% overall catheter complications for pelvic/abdominal sites when the catheters were removed after each session, in contrast to 11% of various carcinomas where the catheters were left in place.…”

Section: Experimental Backgroundmentioning

confidence: 99%

“…A prospectively randomized trial in glioblastoma multiforme treated by a brachytherapy boost (60 Gy at 0.40-0.60 Gy/h)9 hyperthermia (30 min \ 42.5°C and B50°C, before and after brachytherapy) added after external radiotherapy (59.4 Gy in 1.8 Gy fractions) has recently been published in the USA (12). Despite only 39 patients being randomized to brachytherapy and 40 to brachytherapy plus hyperthermia, the time to progression and survival was significantly improved in the patients who actually had the prescribed therapy: from 33 to 44 weeks (p= 0.045) and from 76 to 85 weeks (p=0.02), respectively.…”

Section: Interstitial Thermoradiotherapymentioning

confidence: 99%

See 1 more Smart Citation

Status of Clinical Hyperthermia

Dahl

Dalene²,

Bc³

et al. 1999

Acta Oncologica

View full text Add to dashboard Cite

“…Hyperthermia has also been shown to be a viable adjunct to chemotherapy and radiotherapy [1][2][3][4][5][6][7]. Other types of thermal therapy, such as high temperature ablation therapies, are being investigated as well [8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Non-invasive estimation of hyperthermia temperatures with ultrasound

Arthur

Straube

Trobaugh

et al. 2005

International Journal of Hyperthermia

206

134

View full text Add to dashboard Cite

Ultrasound is an attractive modality for temperature monitoring because it is non-ionizing, convenient, inexpensive and has relatively simple signal processing requirements. This modality may be useful for temperature estimation if a temperature-dependent ultrasonic parameter can be identified, measured and calibrated. The most prominent methods for using ultrasound as a non-invasive thermometer exploit either (1) echo shifts due to changes in tissue thermal expansion and speed of sound (SOS), (2) variation in the attenuation coefficient or (3) change in backscattered energy from tissue inhomogeneities. The use of echo shifts has received the most attention in the last decade. By tracking scattering volumes and measuring the time shift of received echoes, investigators have been able to predict the temperature from a region of interest both theoretically and experimentally in phantoms, in isolated tissue regions in vitro and preliminary in vivo studies. A limitation of this method for general temperature monitoring is that prior knowledge of both SOS and thermalexpansion coefficients is necessary. Acoustic attenuation is dependent on temperature, but with significant changes occurring only at temperatures above 50 C, which may lead to its use in thermal ablation therapies. Minimal change in attenuation, however, below this temperature range reduces its attractiveness for use in clinical hyperthermia. Models and measurements of the change in backscattered energy suggest that, over the clinical hyperthermia temperature range, changes in backscattered energy are dependent on the properties of individual scatterers or scattering regions. Calibration of the backscattered energy from different tissue regions is an important goal of this approach. All methods must be able to cope with motion of the image features on which temperature estimates are based. A crucial step in identifying a viable ultrasonic approach to temperature estimation is its performance during in vivo tests.

show abstract

Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology

Cited by 234 publications

References 28 publications

Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours

Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours

Status of Clinical Hyperthermia

Non-invasive estimation of hyperthermia temperatures with ultrasound

Contact Info

Product

Resources

About